FGI-103

FGI-103
Legal status
Legal status
Identifiers
  • 2-[(E)-2-(5-carbamimidoyl-1-benzofuran-2-yl)ethenyl]-3H-benzimidazole-5-carboximidamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC19H16N6O
Molar mass344.378 g·mol−1
3D model (JSmol)
  • N=C(N)c4ccc3oc(C=Cc2nc1cc(C(=N)N)ccc1[nH]2)cc3c4
  • InChI=1S/C19H16N6O/c20-18(21)10-2-5-16-12(7-10)8-13(26-16)3-6-17-24-14-4-1-11(19(22)23)9-15(14)25-17/h1-9H,(H3,20,21)(H3,22,23)(H,24,25)/b6-3+
  • Key:OOKWWPFCCCMWIS-ZZXKWVIFSA-N

FGI-103 is an antiviral drug developed as a potential treatment for the filoviruses Ebola virus and Marburg virus. In tests on mice FGI-103 was effective against both Ebola and Marburg viruses when administered up to 48 hours after infection. The mechanism of action of FGI-103 has however not yet been established, as it was found not to be acting by any of the known mechanisms used by similar antiviral drugs.[1][2][3]

See also

References

  1. ^ Warren TK, Warfield KL, Wells J, Enterlein S, Smith M, Ruthel G, et al. (May 2010). "Antiviral activity of a small-molecule inhibitor of filovirus infection". Antimicrobial Agents and Chemotherapy. 54 (5): 2152–9. doi:10.1128/AAC.01315-09. PMC 2863630. PMID 20211898.
  2. ^ Bradfute SB, Warfield KL, Bray M (September 2012). "Mouse models for filovirus infections". Viruses. 4 (9): 1477–508. doi:10.3390/v4091477. PMC 3499815. PMID 23170168.
  3. ^ De Clercq E (January 2015). "Ebola virus (EBOV) infection: Therapeutic strategies". Biochemical Pharmacology. 93 (1): 1–10. doi:10.1016/j.bcp.2014.11.008. PMC 7110990. PMID 25481298.
Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.